Kolexia
Dombret Herve
Médecine générale
Hôpital Saint-Louis
Paris, France
563 Activités
488 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Leucémie-lymphome lymphoblastique à précurseurs B et T Maladie résiduelle Leucémie-lymphome lymphoblastique à précurseurs T Chromosome Philadelphie Leucémie lymphoïde Leucémie-lymphome lymphoblastique à précurseurs B

Industries

Daiichi Sankyo
5 collaboration(s)
Dernière en 2023
Incyte
4 collaboration(s)
Dernière en 2023
Servier
4 collaboration(s)
Dernière en 2023
Amgen
3 collaboration(s)
Dernière en 2023

Dernières activités

Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
Blood   07 mars 2024
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL): A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)
Essai Clinique (Amgen)   01 mars 2024
Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel.
Blood   02 février 2024
Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel.
Blood   31 janvier 2024
ALFAPPP: A Prospective Non-interventional Study Documenting the Management and Outcomes of Adult Patients With Acute Myeloid Leukemia (AML)
Essai Clinique (Acute Leukemia French Association)   30 janvier 2024
QUAZAR AML-001: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Essai Clinique (Celgene)   17 janvier 2024
Prognostic impact of CEBPA mutational subgroups in adult AML.
Leukemia   16 janvier 2024
QuANTUM-First: A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM First)
Essai Clinique (Daiichi Sankyo)   16 novembre 2023
NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients
65th ASH Annual Meeting Abstracts   02 novembre 2023
Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report
65th ASH Annual Meeting Abstracts   02 novembre 2023